Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia Corporation (NASDAQ: LQDA) announced the approval of an employment inducement equity award for Dr. Rajeev Saggar, its new Chief Medical Officer. The award consists of a stock option for 200,000 shares under the Liquidia Corporation 2022 Inducement Plan, granted as a material inducement for his employment. The stock option is exercisable at $3.73 per share, with a ten-year term and a four-year vesting schedule. This strategic move aligns with Liquidia's focus on developing treatments for pulmonary hypertension and related conditions.
Liquidia Corporation (NASDAQ: LQDA) received a favorable ruling from the U.S. Patent Trial and Appeal Board regarding the unpatentability of all claims in U.S. Patent No. 10,716,793, owned by United Therapeutics Corporation. This decision supports the potential final regulatory approval of YUTREPIA, an investigational inhaled drug for pulmonary arterial hypertension (PAH). However, ongoing litigation regarding additional patents may delay YUTREPIA's approval until 2027 or later. The PTAB ruling does not guarantee resolution of the litigation.
Liquidia Corporation (LQDA) announced its inclusion in the US small-cap Russell 2000® Index effective June 27, 2022, signaling growth and increased visibility among institutional investors. This membership, valid for one year, follows Liquidia’s performance within the broader Russell 3000® Index. CEO Roger Jeffs stated this reflects the positive momentum generated over recent years, especially as the company prepares for the potential launch of YUTREPIA®, its inhalation powder product pending FDA approval.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options for a total of 24,800 shares to newly hired non-executive employees under its 2022 Inducement Plan. Each stock option, exercisable at $5.79 per share, represents a component of the employment compensation for the new hires. The options have a ten-year term and vest over four years. This plan complies with Nasdaq Listing Rule 5635(c)(4) and is intended to attract and retain talent within the company.
Liquidia Corporation (NASDAQ: LQDA) granted a stock option for 2,000 shares of its common stock to a newly hired non-executive employee, as part of the 2022 Inducement Plan. This option, exercisable at $4.58 per share, aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducements for new hires. The stock option vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. Liquidia focuses on developing treatments for pulmonary hypertension using its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced the appointment of Dr. Rajeev Saggar as Chief Medical Officer, effective July 18, 2022. Dr. Saggar, an expert in pulmonary diseases, will lead the company's research and regulatory affairs, assisting in the anticipated launch of YUTREPIA™, an inhalation powder for pulmonary arterial hypertension, pending final FDA approval. CEO Roger Jeffs highlighted Dr. Saggar’s extensive experience in clinical development and patient care as vital for Liquidia's growth trajectory. This leadership change is expected to enhance the development of innovative therapies.
Liquidia Corporation (NASDAQ: LQDA) recently presented data on the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the Pulmonary Hypertension Association (PHA) International Conference in Atlanta from June 9-11, 2022. The research focused on Quality of Life (QoL) improvements for pulmonary arterial hypertension (PAH) patients, emphasizing the positive impact of YUTREPIA in both new treatments and transitions from other therapies. The FDA previously issued a tentative approval for YUTREPIA on November 5, 2021, which aims to enhance exercise ability for patients with NYHA Functional Class II-III symptoms.
Liquidia Corporation (NASDAQ: LQDA) has announced its participation in the Jefferies Healthcare Conference, where CFO Michael Kaseta will engage in a fireside chat on June 9, 2022, at 8:00 am ET. The conference runs from June 8 to 10, 2022, in New York City. Investors can access a live webcast of the event on Liquidia’s website, which will be archived for 30 days after the conference.
Liquidia focuses on developing products for pulmonary hypertension using its PRINT® Technology, including its inhalation powder YUTREPIA™ for treating pulmonary arterial hypertension.
MORRISVILLE, N.C., June 2, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced that CFO Michael Kaseta will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:00 am ET. The event runs from June 8-10, 2022, in New York City. A webcast will be available on Liquidia's investor website and archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including YUTREPIA™ inhalation powder for PAH.
Liquidia Corporation (NASDAQ: LQDA) announced the presentation of data on YUTREPIA™ (treprostinil) inhalation powder at the ATS International Conference 2022 in San Francisco. The research, focusing on safety and tolerability in treating pulmonary arterial hypertension (PAH), was presented by Dr. Nicholas P. Hill from Tufts Medical Center. YUTREPIA, an investigational drug, has FDA tentative approval aimed at improving exercise ability in adults with NYHA Functional Class II-III symptoms. The company emphasizes its proprietary PRINT® technology used in the drug's development.